Summary of Study ST003908

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002446. The data can be accessed directly via it's Project DOI: 10.21228/M8G834 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003908
Study TitleColesevelam induced serum and fecal metabolite profile in Mdr2 WT and KO mice - Feces
Study SummaryMultidrug resistance protein 2 (MDR2) is essential for proper bile acid transport, and its deficiency leads to spontaneous development of chronic cholestatic liver disease resembling primary sclerosing cholangitis (PSC). To investigate the metabolic consequences of MDR2 loss and the therapeutic effects of bile acid sequestration, we utilized an Mdr2-knockout mouse model and performed fecal and serum metabolomic profiling. Comparative analyses between Mdr2 wildtype and knockout mice revealed significant alterations in bile acid–related metabolites and inflammatory metabolic signatures. Upon treatment with colesevelam, a clinically approved bile acid sequestrant, we observed a marked attenuation of hepatic inflammation and fibrosis. Metabolomic shifts following colesevelam administration highlighted specific metabolite changes potentially responsible for the observed hepatic improvement. These findings suggest a mechanistic link between bile acid modulation, systemic metabolism, and hepatic pathology, offering insights into the therapeutic potential of metabolic intervention in PSC. Fecal metabolite showed bile acid and indole derivatives was significantly changed by colesevelam treatment
Institute
Kyung Hee University
Last NameJune-Young
First NameLee
AddressKyungheedae-ro 26, Seoul, South Korea
Emailhgod2356@khu.ac.kr
Phone+8210-7720-0118
Submit Date2025-04-30
Num Groups4
Raw Data AvailableYes
Raw Data File Type(s)mzML
Analysis Type DetailLC-MS
Release Date2025-05-14
Release Version1
Lee June-Young Lee June-Young
https://dx.doi.org/10.21228/M8G834
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR002446
Project DOI:doi: 10.21228/M8G834
Project Title:Fecal and serum untargeted metabolomics analysis in MDR2 WT, KO mouse
Project Summary:Colesevelam treatment induces significant change of serum and fecal metabolite profile in Primary sclerosing cholangitis mouse model We aimed to identify metabolites differing between Mdr2 WT and KO mice through fecal and serum metabolomic analyses, and to determine whether changes in specific metabolites induced by the bile acid sequestrant colesevelam contribute to the amelioration of liver pathology.
Institute:Kyung Hee University
Last Name:June-Young
First Name:Lee
Address:Kyungheedae-ro 26, Seoul, South Korea
Email:hgod2356@khu.ac.kr
Phone:+8210-7720-0118

Subject:

Subject ID:SU004043
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090
Genotype Strain:FVB.129P2-Abcb4tm1Bor/J
Gender:Male
Animal Animal Supplier:Jackson
Animal Housing:KyungHee University
Animal Water:Distilled water

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Genotype Treatment
SA430024KO-COL11_Feces_positiveMdr2-knockout Colesevelam
SA430025KO-COL9_Feces_negativeMdr2-knockout Colesevelam
SA430026KO-COL8_Feces_negativeMdr2-knockout Colesevelam
SA430027KO-COL7_Feces_negativeMdr2-knockout Colesevelam
SA430028KO-COL6_Feces_negativeMdr2-knockout Colesevelam
SA430029KO-COL5_Feces_negativeMdr2-knockout Colesevelam
SA430030KO-COL15_Feces_negativeMdr2-knockout Colesevelam
SA430031KO-COL11_Feces_negativeMdr2-knockout Colesevelam
SA430032KO-COL10_Feces_positiveMdr2-knockout Colesevelam
SA430033KO-COL10_Feces_negativeMdr2-knockout Colesevelam
SA430034KO-COL9_Feces_positiveMdr2-knockout Colesevelam
SA430035KO-COL15_Feces_positiveMdr2-knockout Colesevelam
SA430036KO-COL5_Feces_positiveMdr2-knockout Colesevelam
SA430037KO-COL7_Feces_positiveMdr2-knockout Colesevelam
SA430038KO-COL8_Feces_positiveMdr2-knockout Colesevelam
SA430039KO-COL6_Feces_positiveMdr2-knockout Colesevelam
SA430040KO-VEH14_Feces_positiveMdr2-knockout Vehicle
SA430041KO-VEH10_Feces_positiveMdr2-knockout Vehicle
SA430042KO-VEH9_Feces_negativeMdr2-knockout Vehicle
SA430043KO-VEH5_Feces_negativeMdr2-knockout Vehicle
SA430044KO-VEH4_Feces_negativeMdr2-knockout Vehicle
SA430045KO-VEH3_Feces_negativeMdr2-knockout Vehicle
SA430046KO-VEH14_Feces_negativeMdr2-knockout Vehicle
SA430047KO-VEH10_Feces_negativeMdr2-knockout Vehicle
SA430048KO-VEH4_Feces_positiveMdr2-knockout Vehicle
SA430049KO-VEH5_Feces_positiveMdr2-knockout Vehicle
SA430050KO-VEH3_Feces_positiveMdr2-knockout Vehicle
SA430051KO-VEH9_Feces_positiveMdr2-knockout Vehicle
SA430052KO-VEH11_Feces_negativeMdr2-knockout Vehicle
SA430053KO-VEH11_Feces_positiveMdr2-knockout Vehicle
SA430054WT-COL6_Feces_positiveWild-type Colesevelam
SA430055WT-COL8_Feces_negativeWild-type Colesevelam
SA430056WT-COL6_Feces_negativeWild-type Colesevelam
SA430057WT-COL3_Feces_negativeWild-type Colesevelam
SA430058WT-COL2_Feces_negativeWild-type Colesevelam
SA430059WT-COL1_Feces_negativeWild-type Colesevelam
SA430060WT-COL12_Feces_negativeWild-type Colesevelam
SA430061WT-COL12_Feces_positiveWild-type Colesevelam
SA430062WT-COL3_Feces_positiveWild-type Colesevelam
SA430063WT-COL10_Feces_negativeWild-type Colesevelam
SA430064WT-COL8_Feces_positiveWild-type Colesevelam
SA430065WT-COL2_Feces_positiveWild-type Colesevelam
SA430066WT-COL10_Feces_positiveWild-type Colesevelam
SA430067WT-COL1_Feces_positiveWild-type Colesevelam
SA430068WT-VEH14_Feces_positiveWild-type Vehicle
SA430069WT-VEH1_Feces_positiveWild-type Vehicle
SA430070WT-VEH2_Feces_positiveWild-type Vehicle
SA430071WT-VEH4_Feces_positiveWild-type Vehicle
SA430072WT-VEH7_Feces_positiveWild-type Vehicle
SA430073WT-VEH8_Feces_positiveWild-type Vehicle
SA430074WT-VEH11_Feces_positiveWild-type Vehicle
SA430075WT-VEH11_Feces_negativeWild-type Vehicle
SA430076WT-VEH14_Feces_negativeWild-type Vehicle
SA430077WT-VEH1_Feces_negativeWild-type Vehicle
SA430078WT-VEH2_Feces_negativeWild-type Vehicle
SA430079WT-VEH4_Feces_negativeWild-type Vehicle
SA430080WT-VEH7_Feces_negativeWild-type Vehicle
SA430081WT-VEH8_Feces_negativeWild-type Vehicle
Showing results 1 to 58 of 58

Collection:

Collection ID:CO004036
Collection Summary:Fecal and serum samples were collected from Mdr2-knockout and wildtype mice following an 8-week treatment period with either colesevelam or vehicle control. Fecal samples were directly collected at the end of the treatment period, while serum samples were obtained via cardiac puncture immediately prior to liver tissue harvest. For metabolomic analysis, 0.04 g of fecal material and 100 μL of serum were used per sample. All samples were snap-frozen and stored at –80 °C until extraction. No in vitro cell lines were used in this study.
Sample Type:Feces
Collection Location:Feces
Storage Conditions:-80℃

Treatment:

Treatment ID:TR004052
Treatment Summary:FVB/N wild-type (WT, Mdr2+/+) and Mdr2−/− (knock-out, KO) littermate mice were obtained by breeding heterozygous pairs bought from the Jackson Laboratory (Bar Habor, Maine, USA). WT and KO littermates were housed under a 12-hour light/dark cycle, and allowed access to water and a standard chow diet (2918C; Envigo) ad libitum. Both WT and KO mice were randomly assigned to cages for each group (vehicle- and colesevelam-treated) at 3–4 weeks of age. Colesevelam (a BA sequestrant, cas#182815-44-7) was obtained from BOC Sciences (Ramsey Road Shirley, NY, USA). From 7–8 weeks of age, male Mdr2+/+ and Mdr2−/− littermate mice received either a control chow diet or a diet supplemented with 2% (w/w) colesevelam for 8 weeks.
Treatment Compound:normal chow diet or Colesevelam included diet
Treatment Route:oral route
Treatment Dose:2% (w/w) colesevelam
Treatment Doseduration:8 weeks
Treatment Vehicle:normal chow diet

Sample Preparation:

Sampleprep ID:SP004049
Sampleprep Summary:Serum and fecal samples were thawed at 4°C before extraction. Briefly, 100 μL of serum and 0.04 g of feces was added to 900 μL of a solution comprising MeOH:acetonitrile:water (1:1:2, v/v) containing reserpine 10 μM and 0.1% (v/v) formic acid. The serum and fecal solutions were then homogenized by vortexing for 5 min, followed by centrifugation at 13,000 × g at 4°C for 10 min. After centrifugation, the supernatant was filtered through a 0.2 μm pore polytetrafluoroethylene polymer filter and transferred to a new glass vial.
Sampleprep Protocol Filename:JYL_protocol.pdf
Processing Storage Conditions:On ice

Chromatography:

Chromatography ID:CH004865
Chromatography Summary:See protocol file
Methods Filename:JYL_protocol.pdf
Instrument Name:Thermo Vanquish
Column Name:Agilent ZORBAX Eclipse Plus C18 (100 x 2.1mm,3.5um)
Column Temperature:45
Flow Gradient:The gradient started with 95% A for 1min, decreasing to 5% A in 14 min, holding at 5% A for 3 min, moving immediately to 95% A, and then holding at 95% A for 2 min.
Flow Rate:0.5 mL/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN006414
Laboratory Name:Seoul Biohub
Analysis Type:MS
Analysis Protocol File:JYL_protocol.pdf
Acquisition Date:2023.08
Software Version:Xcalibur, version 4.1.31.9
Chromatography ID:CH004865
Has Mz:1
Has Rt:1
Rt Units:Seconds
Results File:ST003908_AN006414_Results.txt
Units:peak area
  
Analysis ID:AN006415
Laboratory Name:Seoul Biohub
Analysis Type:MS
Analysis Protocol File:JYL_protocol.pdf
Acquisition Date:2023.08
Software Version:Xcalibur, version 4.1.31.9
Chromatography ID:CH004865
Has Mz:1
Has Rt:1
Rt Units:Seconds
Results File:ST003908_AN006415_Results.txt
Units:peak area
  logo